Compare DG & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DG | ICUCW |
|---|---|---|
| Founded | 1939 | N/A |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4B | N/A |
| IPO Year | N/A | 2021 |
| Metric | DG | ICUCW |
|---|---|---|
| Price | $132.78 | $0.01 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $127.00 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | N/A |
| Earning Date | 12-04-2025 | N/A |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.79 | N/A |
| Revenue | ★ $42,117,664,000.00 | N/A |
| Revenue This Year | $7.83 | N/A |
| Revenue Next Year | $4.16 | N/A |
| P/E Ratio | $23.00 | ★ N/A |
| Revenue Growth | ★ 4.86 | N/A |
| 52 Week Low | $66.43 | N/A |
| 52 Week High | $135.08 | N/A |
| Indicator | DG | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 75.15 | 39.35 |
| Support Level | $123.86 | $0.01 |
| Resistance Level | $135.08 | $0.01 |
| Average True Range (ATR) | 4.81 | 0.00 |
| MACD | 2.32 | 0.00 |
| Stochastic Oscillator | 93.62 | 70.49 |
With more than 20,000 locations, Dollar General's banner is nearly ubiquitous across the rural United States. Dollar General serves as a convenient shopping destination for fill-in store trips, with its value proposition most relevant to consumers in small communities with a dearth of shopping options. The retailer operates a frugal store of about 7,500 square feet and primarily offers an assortment of branded and private-label consumable items (80% of net sales) such as paper and cleaning products, packaged food, and health and beauty items at low prices. Dollar General also offers a limited assortment of seasonal merchandise, home products, and apparel. The firm sells most items at a price point of $10 or less.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.